Table 1.
Characteristics of patients with intra-cardiac devices in 2018, 2019 and 2020.
| Characteristics | Patients with DM | Patients without DM | p | ||||
|---|---|---|---|---|---|---|---|
| 2018–44P | 2019–55P | 2020–9P | 2018–110P | 2019–142P | 2020–26P | ||
| Male gender | 29–65.9% | 34–61.81% | 5–55.55% | 69–62.72% | 89–62.69% | 19–73.07% | NS |
| Mean age (years) | 67.27 ± 10.3 | 66.65 ± 9.76 | 64 ± 6.22 | 69.35 ± 13 | 69.8 ± 12.22 | 67.53 ± 12 | 0.022 |
| Pacemakers: | 32–72.72% | 35–63.63% | 8–88.88% | 88–80% | 110–77.46% | 18–69.23% | <0.001 |
| single-chamber | 15–46.87% | 16–45.71% | 4–50% | 55–62.5% | 54–% | 10–55.55% | NS |
| dual-chamber | 17–53.12% | 19–54.28% | 4–50% | 33–37.5% | 56–% | 8–44.44% | NS |
| New implants | 12–37.5% | 14–40% | 6–75% | 37–42.04% | 46–% | 13–72.22% | NS |
| Main indication for pacemaker: | |||||||
| AVB | 16–50% | 20–57.14% | 3–37.5% | 39–44.31% | 65–52.52% | 9–50% | NS |
| SSS | 8–25% | 11–31.42% | 3–37.5% | 24–27.27% | 28–26.26% | 8–44.44% | NS |
| CSHS | 1–3.12% | - | - | 3–3.4% | 3–3.03% | 1–5.55% | NS |
| Slow AF | 7–21.87% | 4–11.42% | 2–25% | 12–13.63% | 14–18.18% | - | NS |
| Resynchronization therapy: | 10–22.72% | 16–29.09% | - | 15–13.63% | 17–11.97% | 3–11.53% | 0.002 |
| New implants | 3–30% | 4–25% | - | 6–40% | 8–43.75% | 3–100% | NS |
| Implantable cardioverter: | 2–4.54% | 4–7.27% | 1–11.11^ | 7–6.36% | 15–8.73% | 5–19.23% | NS |
| New implants | 1–50% | 1–25% | 0 | 2–28.57% | 5–27.27% | 1–20% | NS |
Legend: diabetes mellitus—DM; P-patient; p—statistical significance; NS—not statistically significant; atrioventricular block—AVB; sick sinus syndrome—SSS; carotid sinus hypersensitivity—CSHS; atrial fibrillation—AF; Statistical methods: Chi-square test, Fisher exact test (Freeman-Halton extension).